Prognostic Significance of Epidermal Growth Factor Receptor in Patients of Glioblastoma Multiforme

Tripathy, Kalpalata; Das, Bidyutprava; Singh, Ajit Kumar; Misra, Aparajita; Misra, Sanjib; Misra, Sudhansu Sekhar

doi:10.7860/jcdr/2017/30138.10327

Cited by 15 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the low prevalence of this tumor, it accounts for 2.5% of cancer deaths [12] and the survival of patients is 3 months, but treatment leads to higher survival of these patients. Recently, studies have shown that patients with EGFR mutations have responded appropriately to targeted therapy [11]. In our study, the Mean±SD overall survival of patients was 22.3±2.5 months.…”

Section: Discussionsupporting

confidence: 50%

“…The study by Smith et al has found no association between the expression of EGFR with prognosis and survival rate [10]. However, Tripathy et al, have found a significant correlation between the expression of EGFR and survival time [11]. Considering that in previous studies, different results have been reported in terms of EGFR expression and survival rate of patients with GBM, we decided to investigate EGFR expression and its relationship with demographic and prognostic variables and patient survival.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Prognosis and Survival Study in Patients with Glioblastoma Multiform and Its Relationship with EGFR Expression

et al. 2020

View full text Add to dashboard Cite

Background and Aim: Glioblastoma multiforme (GBM) is the most common malignant and invasive tumor of the brain. The relation between prognosis and survival of GBM patients with Epidermal Growth Factor Receptor (EGFR) expression is challenging. Thus, we aimed to evaluate the prognosis and survival of patients with GBM and its relationship with EGFR expression. Materials and Methods: This single-arm cohort study was conducted on 70 patients with GBM during 2012-2018 in Shahid Rahnemoon and Mortaz hospitals. The immunohistochemistry technique was applied to paraffin blocks of brain tumors for examining EGFR expression. Other data were extracted from medical records. To determine the survival rate, the Kaplan–Meier curves were used. A chi-square test was used for the analysis of data. Statistically, p-value <0.05 was assumed significant. Results: The mean survival of patients with GBM was 22.3 ± 2.5 months (95% CI=17.41 - 27.10). In addition, 1, 2- and 5-year survival rates were 90%, 30% and 5%, respectively. The mean survival of patients with negative and positive EGFR was 27.4±7.3 and 20.6±2.4 months, respectively. Besides, 11.1% and 14.3% of patients in negative and positive EGFR groups were alive. There was no significant difference in patient’s survival in terms of EGFR expression (p=0.36). No significant difference was seen between the two groups (EGFR positive and negative groups), regarding the frequency of age, sex, tumor’s anatomical location, and place of living (p>0.05). Conclusion: Based on our study, it seems that the GBM tumor was associated with poor prognosis and a low survival rate. It was also found that the expression of the EGFR gene did not affect the survival rate of patients with GBM. Therefore, its use as a predictor factor for survival and prognosis is questionable.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Introductionmentioning

confidence: 96%

Prognosis and Survival Study in Patients with Glioblastoma Multiform and Its Relationship with EGFR Expression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Genomic analysis suggests survival-related genomic abnormalities in GBM patients, such as epidermal growth factor receptor (EGFR) amplification [12, 13] and isocitrate dehydrogenase 1/2 (IDH1/2) mutations [14, 15], have prognostic value. Some studies show that high expression of EGFR indicated poor prognosis [16], and other research find the IDH mutations are associated with improved survival [17]. From the epigenetic level, O -6-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been demonstrated that it is associated with improved progression-free and overall survival in GBM patients treated with alkylating agents [18].…”

Section: Introductionmentioning

confidence: 99%

Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients

Gao

Guo

et al. 2018

J Transl Med

View full text Add to dashboard Cite

BackgroundGlioblastoma multiform (GBM) is a devastating brain tumor with maximum surgical resection, radiotherapy plus concomitant and adjuvant temozolomide (TMZ) as the standard treatment. Diverse clinicopathological and molecular features are major obstacles to accurate predict survival and evaluate the efficacy of chemotherapy or radiotherapy. Reliable prognostic biomarkers are urgently needed for postoperative GBM patients.MethodsThe protein coding genes (PCGs) and long non-coding RNA (lncRNA) gene expression profiles of 233 GBM postoperative patients were obtained from The Cancer Genome Atlas (TCGA), TANRIC and Gene Expression Omnibus (GEO) database. We randomly divided the TCGA set into a training (n = 76) and a test set (n = 77) and used GSE7696 (n = 80) as an independent validation set. Survival analysis and the random survival forest algorithm were performed to screen survival associated signature.ResultsSix PCGs (EIF2AK3, EPRS, GALE, GUCY2C, MTHFD2, RNF212) and five lncRNAs (CTD-2140B24.6, LINC02015, AC068888.1, CERNA1, LINC00618) were screened out by a risk score model and formed a PCG-lncRNA signature for its predictive power was strongest (AUC = 0.78 in the training dataset). The PCG-lncRNA signature could divide patients into high- risk or low-risk group with significantly different survival (median 7.47 vs. 18.27 months, log-rank test P < 0.001) in the training dataset. Similar result was observed in the test dataset (median 11.40 vs. 16.80 months, log-rank test P = 0.001) and the independent set (median 8.93 vs. 16.22 months, log-rank test P = 0.007). Multivariable Cox regression analysis verified that it was an independent prognostic factor for the postsurgical patients with GBM. Compared with IDH mutation status, O-(6)-methylguanine DNA methyltransferase promoter methylation status and age, the signature was proved to have a superior predictive power. And stratified analysis found that the signature could further separated postoperative GBM patients who received TMZ-chemoradiation into high- and low-risk groups in TCGA and GEO dataset.ConclusionsThe PCG-lncRNA signature was a novel prognostic marker to predict survival and TMZ-chemoradiation response in GBM patients after surgery.Electronic supplementary materialThe online version of this article (10.1186/s12967-018-1744-8) contains supplementary material, which is available to authorized users.

show abstract

“…Backflow-free catheters are under evaluation to increase the flow rates at higher values to mitigate this phenomenon [84]. CED was investigated for the delivery of various agents, such as conventional chemotherapy [86], cytotoxin-ligand conjugates targeting cell surface receptors [87], antisense oligonucleotides [86,88], and nanovectors [86,89]. CED showed promising results when used to infuse brain-penetrating nanoparticles (BPNP) that resulted in significant tissue penetration thanks to their small size and their stability as monodispersed agents and allowed for drug release in a controlled fashion.…”

Section: Bypassing the Bbbmentioning

confidence: 99%

Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer

et al. 2019

View full text Add to dashboard Cite

Brain tumors are characterized by very high mortality and, despite the continuous research on new pharmacological interventions, little therapeutic progress has been made. One of the main obstacles to improve current treatments is represented by the impermeability of the blood vessels residing within nervous tissue as well as of the new vascular net generating from the tumor, commonly referred to as blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), respectively. In this review, we focused on established and emerging strategies to overcome the blood-brain barrier to increase drug delivery for brain cancer. To date, there are three broad strategies being investigated to cross the brain vascular wall and they are conceived to breach, bypass, and negotiate the access to the nervous tissue. In this paper, we summarized these approaches highlighting their working mechanism and their potential impact on the quality of life of the patients as well as their current status of development.

show abstract

Prognostic Significance of Epidermal Growth Factor Receptor in Patients of Glioblastoma Multiforme

Abstract: EGFR negative patients respond better to therapy along with longer duration of survival as compared to EGFR positive patient.

Cited by 15 publications

References 16 publications

Prognosis and Survival Study in Patients with Glioblastoma Multiform and Its Relationship with EGFR Expression

Prognosis and Survival Study in Patients with Glioblastoma Multiform and Its Relationship with EGFR Expression

Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients

Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer

Contact Info

Product

Resources

About